Baricitinib. Who makes it? Of course, Eli Lilly.
Post# of 154720
(Total Views: 559)
Posted On: 02/13/2021 4:10:31 PM
Re: ombowstring #77752
Baricitinib. Who makes it? Of course, Eli Lilly.
It's used w/ remdesivir (from Gilead)
$25,000 per year, 60% below Humira's list price of $60,000 per year, said Lilly.Jun 1, 2018
$2,493 for a supply of 30 tablets
would you prescribe this to a COVID patient?
The active substance in Olumiant, baricitinib, is an immunosuppressant
Common side effects of Olumiant include: upper respiratory tract infections (common cold, sinus infections), nausea, cold sores (herpes simplex), and.May 26, 20
Black Box Warnings - perfect for COVID?
Serious infections
Baricitinib increases risk for developing serious infections that may lead to hospitalization or death
Most patients who developed these infections were taking concomitant immunosuppressants (eg, methotrexate, corticosteroids)
If a serious infection develops, interrupt dosing until the infection is controlled
Reported infections include:
Active TB, which may present with pulmonary or extrapulmonary disease; test patients for latent TB before initiating and during therapy; treatment for latent infection should be considered before initiating
Invasive fungal infections, including candidiasis and pneumocystosis; patients with invasive fungal infections may present with disseminated, rather than localized, disease
Bacterial, viral, and other infections due to opportunistic pathogen
Thrombosis
Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), observed at an increased incidence in patients treated with baricitinib compared with placebo
Additionally, cases of arterial thrombosis reported
Many of these adverse events were serious and some resulted in death
Patients with symptoms of thrombosis should be promptly evaluated
https://reference.medscape.com/drug/olumiant-...-1000107#5
It's used w/ remdesivir (from Gilead)
$25,000 per year, 60% below Humira's list price of $60,000 per year, said Lilly.Jun 1, 2018
$2,493 for a supply of 30 tablets
would you prescribe this to a COVID patient?
The active substance in Olumiant, baricitinib, is an immunosuppressant
Common side effects of Olumiant include: upper respiratory tract infections (common cold, sinus infections), nausea, cold sores (herpes simplex), and.May 26, 20
Black Box Warnings - perfect for COVID?
Serious infections
Baricitinib increases risk for developing serious infections that may lead to hospitalization or death
Most patients who developed these infections were taking concomitant immunosuppressants (eg, methotrexate, corticosteroids)
If a serious infection develops, interrupt dosing until the infection is controlled
Reported infections include:
Active TB, which may present with pulmonary or extrapulmonary disease; test patients for latent TB before initiating and during therapy; treatment for latent infection should be considered before initiating
Invasive fungal infections, including candidiasis and pneumocystosis; patients with invasive fungal infections may present with disseminated, rather than localized, disease
Bacterial, viral, and other infections due to opportunistic pathogen
Thrombosis
Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), observed at an increased incidence in patients treated with baricitinib compared with placebo
Additionally, cases of arterial thrombosis reported
Many of these adverse events were serious and some resulted in death
Patients with symptoms of thrombosis should be promptly evaluated
https://reference.medscape.com/drug/olumiant-...-1000107#5
(0)
(0)